

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### **STA Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### **Consultation**

- |  |
|--|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?  |
| Yes. The committee was mindful that EGFR mutation-positive NSCLC is more common in women and people from Asian ethnic groups. It considered whether its recommendations would restrict access to these groups. |

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No other equality concerns were raised in the submissions, expert statements or academic report  |

- |   |
|---|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?  |
| Yes, committee noted that amivantamab plus lazertinib may also have different efficacy in people over 65. The committee were mindful that age is a protected characteristic but its recommendation did not restrict access to treatment for some people over others |

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A	

7.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Section 3.13 of the draft guidance	

**Approved by Associate Director (name):** ...Emily Crowe

**Date:** 27/06/2025